- ¥7bn
- ¥4bn
- ¥9bn
- 77
- 58
- 62
- 78
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.74 | ||
Price to Tang. Book | 0.76 | ||
Price to Free Cashflow | 103.33 | ||
Price to Sales | 0.71 | ||
EV to EBITDA | 7.98 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 3.6% | ||
Return on Equity | 3.83% | ||
Operating Margin | 4.01% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | ¥m | 7,590 | 8,092 | 9,231 | 9,553 | 9,340 | n/a | n/a | 5.16% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +10.91 | +133.74 | +11.59 | -27.06 | -21.6 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
COSMO BIO COMPANY,LIMITED is a Japan-based company mainly engaged in purchase and wholesale of research reagents, equipment, consignment services and clinical test drugs related to life science. Research reagents business imports majority research reagents from United States and Europe, which are prioritized in life science related research. In the equipment business, the Company handles equipment specialized in life science research, purchases goods from a wide range of domestic and overseas, and mainly sells it to the domestic market. The equipment includes ultrasonic cell disruption equipment, bioimaging related equipment and research consumables. The Company provides clinical test drugs mainly used at hospitals and testing centers.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- August 25th, 1983
- Public Since
- September 27th, 2005
- No. of Shareholders
- 4,941
- No. of Employees
- 155
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 5,859,017
- Address
- Toyo-Ekimae Bldg., 2-2-20, Toyo, KOTO-KU, 135-0016
- Web
- https://www.cosmobio.com/
- Phone
- +81 356329600
- Auditors
- A & A Partners Audit
Upcoming Events for 3386
Dividend For 3386.T - 36.0000 JPY
Similar to 3386
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 20:05 UTC, shares in Cosmo Bio Co are trading at ¥1,164. This share price information is delayed by 15 minutes.
Shares in Cosmo Bio Co last closed at ¥1,164 and the price had moved by +19.51% over the past 365 days. In terms of relative price strength the Cosmo Bio Co share price has underperformed the Nikkei 225 Index by -3.54% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Cosmo Bio Co dividend yield is 2.58% based on the trailing twelve month period.
Last year, Cosmo Bio Co paid a total dividend of ¥30, and it currently has a trailing dividend yield of 2.58%.Looking ahead, shares in Cosmo Bio Co are due to go ex-dividend on 2024-12-27 and the next dividend pay date is 2025-03-01.
Cosmo Bio Co are due to go ex-dividend on 2024-12-27 and the next dividend pay date is 2025-03-01. The historic dividend yield on Cosmo Bio Co shares is currently 2.58%.
To buy shares in Cosmo Bio Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥1,164, shares in Cosmo Bio Co had a market capitalisation of ¥7bn.
Here are the trading details for Cosmo Bio Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 3386
Based on an overall assessment of its quality, value and momentum Cosmo Bio Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cosmo Bio Co. Over the past six months, its share price has outperformed the Nikkei 225 Index by +16.9%.
As of the last closing price of ¥1,164, shares in Cosmo Bio Co were trading +14.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cosmo Bio Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥1,164.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cosmo Bio Co's management team is headed by:
- Haruhisa Sakurai - PRE
- Norihiko Shibayama - MDR
- Junko Tochigi - OTH
- Kazuya Shimamura - IND